Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the H.C. Wainwright Global Investment Conference.
Chairman and CEO Ron Bentsur will deliver a corporate presentation that will be available for on-demand viewing by conference attendees starting September 5, 2025, at 7:00 a.m. ET. The company will also participate in virtual one-on-one meetings during the conference, which runs from September 8-10, 2025.
Nuvectis Pharma (NASDAQ: NVCT), azienda biofarmaceutica in fase clinica specializzata in terapie oncologiche di precisione, ha annunciato la sua partecipazione al H.C. Wainwright Global Investment Conference.
Il presidente e CEO Ron Bentsur terrà una presentazione aziendale disponibile on-demand per i partecipanti alla conferenza a partire dal 5 settembre 2025 alle 7:00 ET. La società parteciperà inoltre a incontri virtuali one-to-one durante la conferenza, che si svolgerà dal 8 al 10 settembre 2025.
Nuvectis Pharma (NASDAQ: NVCT), una compañía biofarmacéutica en fase clínica especializada en medicamentos oncológicos de precisión, ha anunciado su participación en la H.C. Wainwright Global Investment Conference.
El presidente y CEO Ron Bentsur ofrecerá una presentación corporativa que estará disponible on‑demand para los asistentes a la conferencia a partir del 5 de septiembre de 2025 a las 7:00 a.m. ET. La compañía también participará en reuniones virtuales individuales durante la conferencia, que se celebrará del 8 al 10 de septiembre de 2025.
Nuvectis Pharma (NASDAQ: NVCT), 정밀 종양학 치료제를 개발하는 임상 단계 바이오제약사인 이 회사가 H.C. Wainwright Global Investment Conference에 참가한다고 발표했습니다.
회장 겸 CEO인 Ron Bentsur가 기업 발표를 진행하며, 해당 발표는 2025년 9월 5일 오전 7:00(동부시간)부터 컨퍼런스 참가자들이 온디맨드로 시청할 수 있습니다. 회사는 또한 2025년 9월 8일~10일에 열리는 컨퍼런스 기간 동안 가상 일대일 미팅에도 참여할 예정입니다.
Nuvectis Pharma (NASDAQ: NVCT), une société biopharmaceutique en phase clinique spécialisée dans les médicaments d'oncologie de précision, a annoncé sa participation à la H.C. Wainwright Global Investment Conference.
Le président et CEO Ron Bentsur donnera une présentation d'entreprise qui sera disponible en mode à la demande pour les participants à partir du 5 septembre 2025 à 7h00 ET. La société participera également à des réunions virtuelles individuelles pendant la conférence, qui se déroulera du 8 au 10 septembre 2025.
Nuvectis Pharma (NASDAQ: NVCT), ein biopharmazeutisches Unternehmen in klinischer Entwicklung, das sich auf Präzisionsonkologie spezialisiert hat, hat seine Teilnahme an der H.C. Wainwright Global Investment Conference angekündigt.
Vorsitzender und CEO Ron Bentsur wird eine Unternehmenspräsentation halten, die ab dem 5. September 2025 um 7:00 Uhr ET für Konferenzteilnehmer on‑demand verfügbar sein wird. Das Unternehmen wird außerdem während der Konferenz, die vom 8. bis 10. September 2025 stattfindet, an virtuellen Einzelgesprächen teilnehmen.
- None.
- None.
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executive Officer, will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the conference taking place September 8-10, 2025.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company’s assets include two clinical-stage drug candidates, NXP900 and NXP800. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and the Phase 1b program has been initiated. NXP800 is an oral small molecule GCN2 activator that has demonstrated anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer, and may be explored in the future in other cancer types. For additional information about Nuvectis Pharma please visit: https://nuvectis.com.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Nuvectis Pharma (NVCT) presenting at the H.C. Wainwright Conference 2025?
Who will present for Nuvectis Pharma at the H.C. Wainwright Conference?
What type of company is Nuvectis Pharma (NVCT)?
When are the one-on-one meetings for Nuvectis Pharma at the H.C. Wainwright Conference?
